Strides Pharma Science Ltd. (formerly known as Strides Shasun Ltd.) has set a revenue target of $200-400m over the next two to four years for the injectables business housed under Stelis Biopharma Pvt Ltd., a company in which it is a majority shareholder.
In a presentation to investors on 5 December outlining its strategy to get to $800m in group sales over the next four years, Strides laid substantial emphasis on its biosimilar efforts under Stelis, while also mentioning additional generic product approvals in